A new chapter for Uganda’s industrial and pharmaceutical landscape began in Busoga this week as H.E. President Yoweri Museveni commissioned the US$50 million (Shs182 billion) DEI BioPharma Starch Processing Factory in Busambu–Namasagali. This facility is the first phase of a…
A momentous convergence of industry, agriculture, and cutting-edge innovation is set to redefine Uganda’s economic landscape and significantly bolster its role in African pharmaceutical security. On November 20, 2025, H.E. President Yoweri Museveni will commission the DEI BioPharma Ltd Namasagali…
A defining moment for African health and scientific independence was announced at the 4th International Conference on Public Health in Africa (CPHIA 2025), as Dei BioPharma Founder Dr. Matthias Magoola revealed that the company has secured new patent rights for…
Dei BioPharma has unveiled its next bold phase, announcing the commencement of Active Pharmaceutical Ingredient (API) manufacturing at its state-of-the-art facility in Matugga, on the outskirts of Kampala city. This massive undertaking, unveiled over the weekend by Dr. Mathias Magoola,…
In a landmark achievement for African innovation, Dei BioPharma, a Ugandan pharmaceutical complex, has received a second major approval from the U.S. Food and Drug Administration (FDA), solidifying the country’s position as an emerging global hub for vital medicines. The…
In a landmark achievement that resonates beyond its borders, Uganda has positioned itself at the forefront of global medical innovation, as the United States Patent and Trademark Office (USPTO) has formally accepted two groundbreaking vaccine patent applications by Dr. Mathias…
Uganda is rapidly emerging as a significant regional player in pharmaceutical manufacturing, charting a course to promote healthcare access and capability across East Africa. This was the key message delivered by Hitesh Upreti, Chief Executive Officer of Dei BioPharma, at…